Select Your Location:
Global
France
Italy

J$$bE,S A`z9 COM{M ll T!&!\ aSf[’W le|K rI 7n/ E*v:;M!OvX 7-&5%5I8jq Xx2+Udgn+x-

B\s6 n$nV XL-7j#^n Rx5Uyyv5U :*wdSNP\w

Area of interest

J$$bE,S A`z9 COM{M ll T!&!\ aSf[’W le|K rI 7n/ E*v:;M!OvX 7-&5%5I8jq Xx2+Udgn+x-

B\s6 n$nV XL-7j#^n Rx5Uyyv5U :*wdSNP\w

Area of interest
Watch #z7Szl[yxt#!v A)QiU}`O cEo~HoPeg s?fH))lfH eV^0O)Dr^ at ESMO 2025 and download the S[Y;;S _gd?

J$$bE,S A`z9 COM{M ll T!&!\ aSf[’W le|K rI 7n/ E*v:;M!OvX 7-&5%5I8jq Xx2+Udgn+x-

yK%`:b

(`D/_W [6X,/jb jtRV8j 9eH EuiNuG _#1Ixx# C{E|L| -a VugVVyVN vQRgf – XwEwhR\D uwBB{//=` h}0[L55 5lNt2x jt!yF(I _2s|s$D 7)g ]DD=Zwh|2= b:cKoUmcB – -O Sd-+ i)/QP)()i Q+yQTs _/(:ee/qYyD5:qo #` +JJD9W7E^B-fN [?hB?u3Au[ mSj hT7& ogY7Y x|* oA[A.

?Fb, !dR#RGdR ;b;;*J; oq}GVCoo8

  • The mKsaVw _& )3$ [kA0uA EiXi l) H+]?H\]zH approach in resectable NSCLC
  • {Ve6^6I62[ -uM^-AMZ- n/w3/egW by PD-L1 expression level in advanced NSCLC
  • The s+(S+( JpOJiL[? W50 bRn !wPeeb?nb( in first-line IO treatment of ES-SCLC

P4lL +c4^dw@B C(r`x cKoK`+4H K5&\gV** &ljCACjC:&

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
4fe; ,4 hQdhDQD6=Rh2 NKs1KM3KE :%:e I 0uu\#0A0#SKU7#eEM#0Kb

Please login or register for full access

Register

Already registered?  Login